Intranasal delivery of chitosan decorated nanostructured lipid carriers of Buspirone for brain targeting: Formulation development, optimization and In-Vivo preclinical evaluation

Noorulla, K. M.; Yasir, Mohd; Muzaffar, Faizi; Roshan, S; Ghoneim, Mohammed M.; Almurshedi, Alanood S.; Tura, Abdurazak J.; Alshehri, Sultan; Gebissa, Teshome; Mekit, Shimelis; Ahmed, Mohammed Muqtader; Zafar, Ameeduzzafar

doi:10.1016/j.jddst.2021.102939

Cited by 24 publications

(12 citation statements)

References 33 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…These kinds of nanocontainers are exemplified in this paper by chitosomes formed due to the electrostatic interaction of liposomes and Cs [32,33,35]. Cs and its derivatives are successfully used as a liposome shell for drug delivery through the mucous membranes of the nose [36], eyes [37], mouth [38], and digestive system [39]. Cs can interact with negatively charged fragments, mainly with sialic acid in the mucous layers, due to its positively charged amino groups [40].…”

Section: Introductionmentioning

confidence: 99%

Therapy of Organophosphate Poisoning via Intranasal Administration of 2-PAM-Loaded Chitosomes

et al. 2022

View full text Add to dashboard Cite

Chitosan-decorated liposomes were proposed for the first time for the intranasal delivery of acetylcholinesterase (AChE) reactivator pralidoxime chloride (2-PAM) to the brain as a therapy for organophosphorus compounds (OPs) poisoning. Firstly, the chitosome composition based on phospholipids, cholesterol, chitosans (Cs) of different molecular weights, and its arginine derivative was developed and optimized. The use of the polymer modification led to an increase in the encapsulation efficiency toward rhodamine B (RhB; ~85%) and 2-PAM (~60%) by 20% compared to conventional liposomes. The formation of monodispersed and stable nanosized particles with a hydrodynamic diameter of up to 130 nm was shown using dynamic light scattering. The addition of the polymers recharged the liposome surface (from −15 mV to +20 mV), which demonstrates the successful deposition of Cs on the vesicles. In vitro spectrophotometric analysis showed a slow release of substrates (RhB and 2-PAM) from the nanocontainers, while the concentration and Cs type did not significantly affect the chitosome permeability. Flow cytometry and fluorescence microscopy qualitatively and quantitatively demonstrated the penetration of the developed chitosomes into normal Chang liver and M-HeLa cervical cancer cells. At the final stage, the ability of the formulated 2-PAM to reactivate brain AChE was assessed in a model of paraoxon-induced poisoning in an in vivo test. Intranasal administration of 2-PAM-containing chitosomes allows it to reach the degree of enzyme reactivation up to 35 ± 4%.

show abstract

Section: Introductionmentioning

confidence: 99%

Therapy of Organophosphate Poisoning via Intranasal Administration of 2-PAM-Loaded Chitosomes

et al. 2022

View full text Add to dashboard Cite

show abstract

“…Lipid-based nanocarriers have also been investigated for IN drug delivery thanks to their low toxicity, biocompatibility, biodegradability and flexibility. In particular, second-generation lipid carriers, solid lipid nanocarriers (SLNs) and nanostructured lipid carriers (NLPs) have been mainly studied [ 56 , 62 , 63 , 69 ]. SLNs are composed of a solid lipid core containing the drug stabilized by surfactants, while NLPs possess a solid lipid core with a surfactant outer shell.…”

Section: Biomaterials-based Vehicles For In Drug Deliverymentioning

confidence: 99%

Biomaterials-Enhanced Intranasal Delivery of Drugs as a Direct Route for Brain Targeting

Marcello

Chiono

2023

IJMS

View full text Add to dashboard Cite

Intranasal (IN) drug delivery is a non-invasive and effective route for the administration of drugs to the brain at pharmacologically relevant concentrations, bypassing the blood–brain barrier (BBB) and minimizing adverse side effects. IN drug delivery can be particularly promising for the treatment of neurodegenerative diseases. The drug delivery mechanism involves the initial drug penetration through the nasal epithelial barrier, followed by drug diffusion in the perivascular or perineural spaces along the olfactory or trigeminal nerves, and final extracellular diffusion throughout the brain. A part of the drug may be lost by drainage through the lymphatic system, while a part may even enter the systemic circulation and reach the brain by crossing the BBB. Alternatively, drugs can be directly transported to the brain by axons of the olfactory nerve. To improve the effectiveness of drug delivery to the brain by the IN route, various types of nanocarriers and hydrogels and their combinations have been proposed. This review paper analyzes the main biomaterials-based strategies to enhance IN drug delivery to the brain, outlining unsolved challenges and proposing ways to address them.

show abstract

“…CTN can also improve drug permeation blood-brain barrier (BBB) due to its ability to open tight junctions between cells [11]. Brigatinib loaded in PLGA nanoparticles coated with CTN was explored for treating non-small cell lung cancer [12].CTN-coated Buspirone-loaded nanostructured lipid carriers for intranasal delivery used for a nose to brain delivery [13]. In Vivo, Pharmacokinetic Studies of CTN-coated PLGA-based NPs showed enhanced bioavailability of Olaparib [14].…”

Section: Of 21mentioning

confidence: 99%

Development and Characterization of Chitosan-Based Spray-Dried Solid Dispersions of Apigenin: 3D Printed Shell-Pill for Improved Efficacy of Model Flavonoid

Alali¹,

Ahmed²,

Fatima³

et al. 2023

Preprint

View full text Add to dashboard Cite

This study aimed to develop chitosan-based apigenin spray dried solid dispersion using 1:1,1:1.5,1:2 w/w ratios. The results of process yield and drug assay were found to be (87.5%, 94.2%, and 95.86%), (95.2 ±1.34%), (99.5 ±0.85%), and (97.6 ±2.42%), respectively, for AC1, AC2, and AC3. Flow properties indicate the free flow of powders. FTIR revealed compatibility among chitosan and apigenin, and DSC and XRD showed prepared solid dispersion was on a molecular level and available in amorphous. In contrast, SEM images reflect irregular block and near-spherical shape elongated particles in the selected AC2. The antimicrobial examination reflects that AC2 was more effective against Gram-positive, negative, and fungal strains. AC2 SDSDs has more anti-oxidant property compared to pure flavonoid (AGN). Anti-proliferative activity against A549 lung cancer cell lines showed better anti-cancer activity by AC2 SDSDs. The selected AC2 SDSD filled in a 3D shell pill and further characterized for 3D shell pill for dissolution profiles and stability studies. The product has sustained release and similar release profiles after three months of storage. The findings suggest that the AC2 SDSDs may be a promising candidate for further development as a 3D printed drug delivery system for treating multiple disease conditions using model flavonoid- apigenin.

show abstract

Intranasal delivery of chitosan decorated nanostructured lipid carriers of Buspirone for brain targeting: Formulation development, optimization and In-Vivo preclinical evaluation

Cited by 24 publications

References 33 publications

Therapy of Organophosphate Poisoning via Intranasal Administration of 2-PAM-Loaded Chitosomes

Therapy of Organophosphate Poisoning via Intranasal Administration of 2-PAM-Loaded Chitosomes

Biomaterials-Enhanced Intranasal Delivery of Drugs as a Direct Route for Brain Targeting

Development and Characterization of Chitosan-Based Spray-Dried Solid Dispersions of Apigenin: 3D Printed Shell-Pill for Improved Efficacy of Model Flavonoid

Contact Info

Product

Resources

About